InVivoMAb anti-mouse CD83

Onyshchenko K, Luo R, Rao X, et al. Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models. Theranostics. 2024,14(6):2573-2588. doi: 10.7150/thno.88864

Rotem S, Bar-Haim E, Elia U, et al. A Novel Approach to Vaccine Development: Concomitant Pathogen Inactivation and Host Immune Stimulation by Peroxynitrite. Vaccines (Basel). 2022,10(10). doi: 10.3390/vaccines10101593

Carlsson JA, Wold AE, Sandberg AS, et al. The Polyunsaturated Fatty Acids Arachidonic Acid and Docosahexaenoic Acid Induce Mouse Dendritic Cells Maturation but Reduce T-Cell Responses In Vitro. PLoS One. 2015,10(11):e0143741. doi: 10.1371/journal.pone.0143741

Kretschmer B, Lüthje K, Schneider S, et al. Engagement of CD83 on B cells modulates B cell function in vivo. J Immunol. 2009,182(5):2827-34. doi: 10.4049/jimmunol.0803153

Lüthje K, Cramer SO, Ehrlich S, et al. Transgenic expression of a CD83-immunoglobulin fusion protein impairs the development of immune-competent CD4-positive T cells. Eur J Immunol. 2006,36(8):2035-45.